← All indications
Hemophilia A
The classic hemophilia resulting from a deficiency of factor VIII. It is an inherited disorder of blood coagulation characterized by a permanent tendency to hemorrhage.
Drugs by status
Approved for this indication (21)
- desmopressin
- antihemophilic factor viii (Recombinant), porcine sequence
- concizumab
- antihemophilic factor viii (Recombinant), Fc-fusion protein
- emicizumab
- Marstacimab
- coagulation factor viia (recombinant)
- turoctocog alfa
- antihemophilic factor viii (Recombinant)
- tranexamic acid
- anti-inhibitor coagulant complex (activated prothrombin complex concentrate)
- antihemophilic factor viii human
- rurioctocog alfa pegol
- fitusiran
- antihemophilic factor viii (Recombinant), single chain
- valoctocogene roxaparvovec
- bivv001
- etranacogene dezaparvovec
- moroctocog-alfa
- antihemophilic factor (recombinant), fc-vwf-xten fusion protein-ehtl
- sct800
Phase 4 trials (16)
Phase 3 trials (18)
- methylprednisolone
- bacille calmette-guerin
- coagulation factor ix (Recombinant)
- csl689
- alpha-1 antitrypsin
- nonacog beta pegol
- human factor ix complex (prothrombin complex concentrate)
- cyclophosphamide
- vatreptacog alfa (activated)
- spk-8011
- antithrombin iii (human)
- eptacog
- marzaa
- nnc0365-3769 a
- aav2/6 human factor viii
- stsp-0601
- mim8
- gs1191
Phase 2 trials (17)
Phase 1 trials (18)
- arc19499
- bay86-6150
- nnc 0128-0000-2011
- marzeptacog alpfa
- allogeneic hematopoietic stem cells
- coagulation factor ix (Recombinant), Fc-fusion protein
- aav2/8-hlp-fviii-v3
- telaprevir
- coagulation factor xiii a-subunit (recombinant)
- sodium chloride
- autologous cd34+pbsc, transduced with a lentiviral vector (-889itga2b-bddfviii-wpts(mut6)(vsvg)
- mg1113
- cd34+ hematopoietic stem cells transduced with cd68-et3 lentiviral vector
- bbm 002
- tu7710
- sr604
- nggt003
- nnc0442-0344
Organizations
Organization Involved with Phase 4 Indications (51)
- CSL Behring
- Swedish Orphan Biovitrum
- Takeda
- Bio Products Laboratory
- Roche
- Merck
- Novo Nordisk
- Grifols
- Pfizer
- Wyeth
- Baxalta
- Bayer
- Bioverativ Therapeutics Inc.
- Sinocelltech Ltd.
- Fondazione Angelo Bianchi Bonomi
- Shahid Beheshti University of Medical Sciences
- Baqiyatallah Medical Sciences University
- Chulalongkorn University
- Lund University
- Ohio State University
- Osaka University
- Sanquin
- Shengjing Hospital
- University of Iowa
- University of Medicine and Dentistry of New Jersey
- University of Milan
- University of Oklahoma
- University of Tehran
- University of Toronto
- Utrecht University
- +21 more
Organization Involved with Phase 3 Indications (54)
- Biomarin
- Catalyst Biosciences
- Aptevo Therapeutics
- Green Cross Corporation
- Shire
- Cangene
- Octapharma
- Genzyme
- Sanofi
- Sanofi-Aventis
- Biogen
- AryoGen Pharmed Co.
- Chugai
- Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- Laboratoire français de Fractionnement et de Biotechnologies
- Parexel
- National Heart, Lung, and Blood Institute (NHLBI)
- University of Pittsburgh
- Central South University
- Emory University
- Georgetown University
- Kunming Medical University
- Memorial Hermann Health System
- Oregon Health and Science University
- Tulane University
- Thomas Jefferson University
- University of Michigan
- University of Oregon
- University of Bonn
- Wayne State University
- +24 more
Organization Involved with Phase 2 Indications (35)
- Octagen
- Avigen
- Ipsen
- Alnylam Pharmaceuticals
- Chiesi
- Dimension Therapeutics
- GWT-TUD GmbH
- PTC Therapeutics
- Recoly N.V.
- Spark Therapeutics
- Ascension Health
- University of Pennsylvania
- Blood Center of Wisconsin
- Case Western Reserve University
- Harvard University
- University of Washington
- Gottfried Wilhelm Leibniz Universität Hannover
- New England Research Institutes
- Shenzhen Geno-Immune Medical Institute
- Stanford University
- University of Sydney
- University of California, Irvine
- University of Campinas
- Cook Children's Medical Center
- Medical University of Vienna
- Opko
- Ultragenyx Inc.
- Rush University
- Sangamo BioSciences
- Hemophilia Center of Western Pennsylvania
- +5 more
Organization Involved with Phase 1 Indications (19)
- Syntonix Pharmaceuticals
- Vertex
- ISU Abxis Co., Ltd.
- Sponsor GmbH
- Medical Research Council
- National Institute of Allergy and Infectious Diseases (NIAID)
- Cairo University
- University of London
- Korea University
- Medical College of Wisconsin
- University of Cincinnati
- Tokyo Metropolitan Komagome Hospital
- Japan Agency for Medical Research and Development
- Hemophilia of Georgia, Inc.
- People's Liberation Army of China
- DreamCIS
- OHARA Pharmaceutical Co., Ltd.
- St. Jude Children's Hospital
- Expression Therapeutics, LLC
Organization Involved with Other Experimental Indications (13)
- Aarhus University
- Cornell University
- Nanjing Medical University
- Nanjing University
- University of Manchester
- Virginia Commonwealth University
- University of Lyon
- City of Hope National Medical Center
- Biotest Pharmaceuticals
- New York Presbyterian Hospital
- Charta Fondazione
- Government of Taiwan
- East China University of Science and Technology